ORG Wealth Partners LLC Has $936,000 Position in Johnson & Johnson $JNJ

ORG Wealth Partners LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 131.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 5,046 shares of the company’s stock after purchasing an additional 2,863 shares during the quarter. ORG Wealth Partners LLC’s holdings in Johnson & Johnson were worth $936,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson in the second quarter valued at about $27,000. Clayton Financial Group LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $28,000. Semmax Financial Advisors Inc. grew its position in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC raised its holdings in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Guggenheim upped their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Loop Capital set a $190.00 price objective on Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Trading Up 1.9%

Johnson & Johnson stock opened at $213.78 on Wednesday. The company has a market cap of $515.06 billion, a price-to-earnings ratio of 20.64, a P/E/G ratio of 2.15 and a beta of 0.34. The firm has a 50-day moving average of $203.88 and a 200-day moving average of $185.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a one year low of $141.50 and a one year high of $215.18.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.04. The business had revenue of $23.99 billion for the quarter, compared to analyst estimates of $23.73 billion. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.Johnson & Johnson’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.42 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware’s top court threw out part of a roughly $1 billion damages award tied to J&J’s 2019 attempt to buy Auris Health and ordered a recalculation — a development that could materially reduce the company’s payout and legal overhang. Johnson & Johnson’s $1 billion loss from robotics takeover reduced by Delaware top court
• Positive Sentiment: J&J reported encouraging long-term Rybrevant results in metastatic colorectal cancer — positive oncology data can raise expectations for revenue and pipeline value in oncology. Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
• Positive Sentiment: MedTech momentum is cited as a near-term growth driver, led by cardiovascular strength and new product ramps — this supports revenue upside ahead of J&J’s Q4 results. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: New depression data (CAPLYTA, SPRAVATO and other analyses) to be presented at ACNP may improve perceptions of J&J’s CNS franchise and long-term drug commercialization prospects. Johnson & Johnson elevates leadership in depression with new data at 2026 ACNP
• Neutral Sentiment: Management’s presentation at the J.P. Morgan Healthcare Conference was published (transcript) — useful for investor modeling but largely reiterates strategy and pipeline priorities rather than new surprises. J&J Presents at 44th Annual J.P. Morgan Healthcare Conference (Transcript)
• Neutral Sentiment: Investor-letter / market commentary pieces note J&J’s strong Q4 contributions as part of broader market trends; these confirm momentum but add little incremental catalyst. Here’s What Lifted Johnson & Johnson (JNJ) in Q4
• Negative Sentiment: Despite the Delaware ruling reducing part of the award, residual legal exposure remains until damages are fully recalculated and any further appeals conclude — some uncertainty and potential liability persist. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Negative Sentiment: Analysts flag lingering China market pressure for MedTech/pharma sales, which could temper near-term international growth even as other regions recover. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.